AbbVie (ABBV) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $90 and the lowest price target forecast is $47. The average forecast of all the analysts is $71.75 and the expected standard deviation is $11.15.
AbbVie (ABBV) : The consensus on AbbVie (ABBV) based on 13 analyst recommendation on the company stock is 2.23, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 6 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Also, In the latest statement by the brokerage house, BMO Capital downgrades its outlook on AbbVie (NYSE:ABBV). The current rating of the shares is Market Perform, according to the research report released by the firm. Previously, the company had a rating of Outperform. The rating by the firm was issued on June 10, 2016.
AbbVie (NYSE:ABBV): The stock opened at $64.10 on Thursday but the bulls could not build on the opening and the stock topped out at $64.14 for the day. The stock traded down to $63.61 during the day, due to lack of any buying support eventually closed down at $64.03 with a loss of -0.11% for the day. The stock had closed at $64.10 on the previous day. The total traded volume was 5,126,674 shares.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.